目的：探索0.05%环孢素A联合奥洛他定滴眼液治疗过敏性结膜炎相关干眼的疗效。

方法：选取广西壮族自治区人民医院2022年8月至2023年4月过敏性结膜炎相关干眼患者63例63眼，按数字表法随机分为对照组(33眼，给予0.1%盐酸奥洛他定滴眼液和0.3%玻璃酸钠滴眼液)和观察组(30眼，给予0.1%盐酸奥洛他定滴眼液和0.05%环孢素A滴眼液)。分别评估两组患者治疗前后的眼表疾病指数(OSDI)、眼部症状总评分(TOSS)、结膜充血评分、结膜乳头和滤泡评分、泪液分泌试验(SⅠt)、泪河高度(TMH)、睑板腺分泌能力评分、睑板腺分泌物性质评分、睑板腺缺失面积评分、角膜荧光素染色(CFS)、泪膜破裂时间(BUT)、非侵入性首次泪膜破裂时间(NIBUTf)、非侵入性平均泪膜破裂时间(NIBUTav)和治疗期间药物安全性。

结果：治疗后观察组患者的OSDI、TOSS评分、结膜充血评分、结膜乳头和滤泡评分、SⅠt、TMH、睑板腺分泌能力评分、睑板腺分泌物性质评分、CFS评分、BUT、NIBUTf、NIBUTav均较治疗前改善(均P<0.017)，其中OSDI、TOSS评分、结膜充血评分、结膜乳头和滤泡评分、BUT、NIBUTf、NIBUTav较对照组改善(均P<0.05)。两组患者治疗前后睑板腺缺失面积评分无差异(P>0.05)。治疗期间两组患者均无局部或全身不良反应。

结论：0.05%环孢素A联合奥洛他定滴眼液治疗可显著改善过敏性结膜炎相关干眼患者眼红、眼痒、异物感等眼部不适症状，提高泪膜稳定性，且安全性好。

METHODS: A total of 63 patients(63 eyes)with allergic conjunctivitis-related dry eye disease in the People's Hospital of Guangxi Zhuang Autonomous Region from August 2022 to April 2023 were enrolled and randomly divided into control group(n=33)and observation group(n=30). The patients of the control group were administrated with 0.1% olopatadine eye drops and 0.3% sodium hyaluronate eye drops, while the observation group was administrated with 0.1% olopatadine eye drops and 0.05% cyclosporine A eye drops. The ocular surface disease index(OSDI), total ocular symptom score(TOSS), conjunctival congestion score, conjunctival papillae and follicle score, Schirmer I test(SⅠt), tear meniscus height(TMH), meibomian gland secretion ability and property score, meibomian gland loss area score, corneal fluorescein staining(CFS), tear film break-up time(BUT), noninvasive first tear film break-up time(NIBUTf), noninvasive average tear film break-up time(NIBUTav)before and after treatment and the drug safety during the treatment period of both groups of patients were evaluated.

RESULTS: After treatment, OSDI, TOSS, conjunctival congestion score, conjunctival papillae and follicle score, SⅠt, TMH, meibomian gland secretion ability score and property score, CFS, BUT, NIBUTf, and NIBUTav of the observation group showed improvements compared with those before treatment(all P<0.017). Among these, OSDI, TOSS, conjunctival congestion score, conjunctival papillae and follicle score, BUT, NIBUTf, and NIBUTav demonstrated significant improvement compared with the control group(all P<0.05). There was no statistically significant difference in meibomian gland loss area score between the two groups before and after treatment(P>0.05). During the treatment period, there were no local or systemic adverse reactions.

CONCLUSION: The combined use of 0.05% cyclosporine A and olopatadine eye drops can significantly improve ocular discomfort symptoms of patients with dry eye disease associated with allergic conjunctivitis, such as red eyes, itchy eyes and foreign body sensation, promote tear film stability and have high safety.